Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
7.80
-0.04 (-0.51%)
At close: Dec 5, 2025, 4:00 PM EST
7.65
-0.15 (-1.92%)
After-hours: Dec 5, 2025, 6:00 PM EST
Kyverna Therapeutics Employees
Kyverna Therapeutics had 112 employees as of December 31, 2024. The number of employees increased by 16 or 16.67% compared to the previous year.
Employees
112
Change (1Y)
16
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,437,429
Market Cap
341.61M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 112 | 16 | 16.67% |
| Dec 31, 2023 | 96 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KYTX News
- 21 days ago - Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential - Seeking Alpha
- 23 days ago - Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 25 days ago - Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance - GlobeNewsWire
- 5 weeks ago - Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 - GlobeNewsWire
- 5 weeks ago - Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 - GlobeNewsWire
- 6 weeks ago - Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis - GlobeNewsWire
- 2 months ago - Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS - GlobeNewsWire